Patients with coronary artery disease presenting to an emergency department with chest pain are likely to undergo hospitalization in an attempt to elucidate its aetiology.
Dr Liuzzo and colleagues from New York examined whether proton-pump inhibitor (PPI) therapy in coronary artery disease patients is associated with fewer chest pain events and evaluations.
The research team identified a veteran patient population with documented coronary artery disease.
The team followed up chest pain episodes, emergency department visits and hospitalizations for chest pain over 2 years.
|70% of patients using proton-pump inhibitors had fewer chest pain episodes|
|Alimentary Pharmacology & Therapeutics|
Patient outcomes between proton-pump inhibitor use and non-use of proton-pump inhibitor therapy were compared.
The researchers noted that in 415 male patients, 23% utilized a proton-pump inhibitor and 77% did not.
The team found that proton-pump inhibitor therapy was associated with fewer chest pain episodes, emergency department visits, and hospitalizations.
The incidence of adverse events was decreased in the proton-pump inhibitor group.
The team observed that 70% of patients had fewer chest pain episodes, 55% had fewer emergency department visits and 53% fewer hospitalizations.
By using multivariate analysis, the team showed that PPI therapy independently predicted a reduced prevalence of chest pain, emergency department visits, and hospitalizations.
Dr Liuzzo's team concluded, “Proton-pump inhibitor therapy for veteran coronary artery disease patients is associated with fewer chest pain episodes, emergency department visits and hospitalizations for chest pain.”